We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
AbbVie Canada on Wednesday said psoriasis treatment Skyrizi is now listed for public payer coverage across Canada, following its addition as a special authorization drug on the formulary of Prince Edward Island.
Skyrizi, or risankizumab, is a prescription medicine used to treat adults with moderate to severe plaque psoriasis and is part of a collaboration between Boehringer Ingelheim and AbbVie, AbbVie Canada said.
The company also said psoriasis affects 1 million Canadians and 125 million people around the world.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 24, 2021 11:47 ET (16:47 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
